Qiagen, DiaSorin launch automated workflow for latent TB

By LabPulse.com staff writers

December 2, 2019 -- Qiagen and DiaSorin have announced the U.S. launch of their automated workflow for QuantiFeron-TB Gold Plus (QFT-Plus), a fourth-generation product for latent tuberculosis (TB) detection, on DiaSorin's Liaison analyzer platforms.

In a statement, the companies said the U.S. Food and Drug Administration (FDA) approved the Liaison QFT-Plus test, which was developed by Qiagen and DiaSorin as a solution for streamlined laboratory automation in latent TB screening. The product supports the conversion from tuberculin skin tests to modern blood-based QuantiFeron technology, according to the companies.

The workflow pairs Qiagen's standard QFT-Plus blood collection tubes, containing the core QuantiFeron technology, with DiaSorin's new Liaison QFT-Plus detection assay.

More than 8,000 Liaison systems have been placed worldwide, primarily in hospital laboratories. The Liaison workflow for QFT-Plus was introduced in Europe in 2018 and is headed for China in 2020. Combined with front-end automation options for liquid handling, the workflow delivers significant gains in turnaround time and efficiency, the companies said.

Qiagen, LabCorp expand partnership
LabCorp plans to tap into Qiagen's Human Gene Mutation Database for rare and inherited conditions across its network of laboratories per an expansion...
Qiagen considers multiple interested suitors
Qiagen announced that it is considering its options after receiving "several conditional, [nonbinding] indications of interest" for its acquisition.
Qiagen TB blood test headed for wider global use
Qiagen's Quantiferon-TB Gold Plus blood test for detecting latent tuberculosis (TB) made the list of diagnostics in the international Stop TB Partnership...
DiaSorin's Simplexa varicella-zoster test gets CE Mark
DiaSorin Molecular has received the CE Mark for its Simplexa VZV Swab Direct assay. The molecular diagnostic makes it possible to detect varicella-zoster...
Qiagen and DiaSorin heed call for better Lyme disease test
Qiagen and DiaSorin are teaming up on the development of a more sensitive test to enable earlier detection of Lyme disease, with plans in 2020 to validate...
DiaSorin Molecular's Simplexa herpes virus test gets CE Mark
DiaSorin Molecular's Simplexa single molecular test for the herpes simplex virus and related varicella-zoster virus now has the CE Mark, the company announced...

Copyright © 2019 LabPulse.com

Last Updated np 12/2/2019 5:42:57 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.